RE:RE: Long Term Hold?Their PD product, pimavanserin, is on an expedited path to an NDA filing and their balance sheet is looking good. Great potential. Very good chances of getting to market and possibly a takeover candidate in my opinion. My guess is those long in ACAD will be very happy in the next couple of years.